Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1747 entries
Sorted by: Best Match Show Resources per page
The race toward equity: increasing racial diversity in cancer research and cancer care

pipeline programs

Weeraratna AT.
GSID: 1D6-A1PpFU0J
DC Brady, AT Weeraratna - Cancer discovery, 2020 - AACR

The Race toward Equity: Increasing Racial Diversity in Cancer Research and Cancer Care Page 1 VIEWS OctOber 2020 CANCER DISCOVERY | OF1 Science in Society The Race …

Cite
Brady, D. C., & Weeraratna, A. T. (2020). The race toward equity: increasing racial diversity in cancer research and cancer care. Cancer discovery, 10(10), 1451-1454.
Brady, Donita C., and Ashani T. Weeraratna. "The race toward equity: increasing racial diversity in cancer research and cancer care." Cancer discovery 10.10 (2020): 1451-1454.
Copy Download .nbib Format: MLA
Serum peptidome profiling for the diagnosis of colorectal cancer: discovery and validation in two independent cohorts.

Oncotarget

Wang H, Luo C, Zhu S, Fang H, Gao Q, Ge S, Qu H, Ma Q, Ren H, Wang Y, Wang W.
PMID: 28938643
Oncotarget. 2017 Jul 26;8(35):59376-59386. doi: 10.18632/oncotarget.19587. eCollection 2017 Aug 29.

Colorectal cancer (CRC) is one of the most common malignant neoplasms worldwide. Except for the existing fecal occult blood test, colonoscopy and sigmoidoscopy, no widely accepted

Cite
Wang H, Luo C, Zhu S, et al. Serum peptidome profiling for the diagnosis of colorectal cancer: discovery and validation in two independent cohorts. Oncotarget. 2017;8(35):59376-59386doi: 10.18632/oncotarget.19587.
Wang, H., Luo, C., Zhu, S., Fang, H., Gao, Q., Ge, S., Qu, H., Ma, Q., Ren, H., Wang, Y., & Wang, W. (2017). Serum peptidome profiling for the diagnosis of colorectal cancer: discovery and validation in two independent cohorts. Oncotarget, 8(35), 59376-59386. https://doi.org/10.18632/oncotarget.19587
Wang, Hao, et al. "Serum peptidome profiling for the diagnosis of colorectal cancer: discovery and validation in two independent cohorts." Oncotarget vol. 8,35 (2017): 59376-59386. doi: https://doi.org/10.18632/oncotarget.19587
Wang H, Luo C, Zhu S, Fang H, Gao Q, Ge S, Qu H, Ma Q, Ren H, Wang Y, Wang W. Serum peptidome profiling for the diagnosis of colorectal cancer: discovery and validation in two independent cohorts. Oncotarget. 2017 Jul 26;8(35):59376-59386. doi: 10.18632/oncotarget.19587. eCollection 2017 Aug 29. PMID: 28938643; PMCID: PMC5601739.
Copy Download .nbib Format: NLM
CD4.

Cancer discovery

[No authors listed]
PMID: 28450427
Cancer Discov. 2017 Jun;7(6):OF3. doi: 10.1158/2159-8290.CD-NB2017-063. Epub 2017 Apr 27.

Temporary removal of CD4

Cite
CD4. Cancer Discov. 2017;7(6):OF3doi: 10.1158/2159-8290.CD-NB2017-063.
(2017). CD4. Cancer discovery, 7(6), OF3. https://doi.org/10.1158/2159-8290.CD-NB2017-063
"CD4." Cancer discovery vol. 7,6 (2017): OF3. doi: https://doi.org/10.1158/2159-8290.CD-NB2017-063
CD4. Cancer Discov. 2017 Jun;7(6):OF3. doi: 10.1158/2159-8290.CD-NB2017-063. Epub 2017 Apr 27. PMID: 28450427.
Copy Download .nbib Format: NLM
Nivolumab Approved for Liver Cancer.

Cancer discovery

[No authors listed]
PMID: 28978557
Cancer Discov. 2017 Nov;7(11):OF3. doi: 10.1158/2159-8290.CD-NB2017-138. Epub 2017 Oct 04.

The FDA granted accelerated approval to nivolumab for second-line treatment of advanced hepatocellular carcinoma, making it just the third drug on the market for the disease. The PD-1 inhibitor is approved for patients who cannot tolerate sorafenib and those...

Cite
Nivolumab Approved for Liver Cancer. Cancer Discov. 2017;7(11):OF3doi: 10.1158/2159-8290.CD-NB2017-138.
(2017). Nivolumab Approved for Liver Cancer. Cancer discovery, 7(11), OF3. https://doi.org/10.1158/2159-8290.CD-NB2017-138
"Nivolumab Approved for Liver Cancer." Cancer discovery vol. 7,11 (2017): OF3. doi: https://doi.org/10.1158/2159-8290.CD-NB2017-138
Nivolumab Approved for Liver Cancer. Cancer Discov. 2017 Nov;7(11):OF3. doi: 10.1158/2159-8290.CD-NB2017-138. Epub 2017 Oct 04. PMID: 28978557.
Copy Download .nbib Format: NLM
Targeting Angiogenesis in Bladder Cancer.

Cancer discovery

[No authors listed]
PMID: 28978558
Cancer Discov. 2017 Nov;7(11):OF2. doi: 10.1158/2159-8290.CD-NB2017-140. Epub 2017 Oct 04.

Findings from the phase III RANGE study indicate that adding ramucirumab to docetaxel may improve progression-free survival for patients with advanced or metastatic urothelial carcinoma whose disease is refractory to platinum chemotherapy.

Cite
Targeting Angiogenesis in Bladder Cancer. Cancer Discov. 2017;7(11):OF2doi: 10.1158/2159-8290.CD-NB2017-140.
(2017). Targeting Angiogenesis in Bladder Cancer. Cancer discovery, 7(11), OF2. https://doi.org/10.1158/2159-8290.CD-NB2017-140
"Targeting Angiogenesis in Bladder Cancer." Cancer discovery vol. 7,11 (2017): OF2. doi: https://doi.org/10.1158/2159-8290.CD-NB2017-140
Targeting Angiogenesis in Bladder Cancer. Cancer Discov. 2017 Nov;7(11):OF2. doi: 10.1158/2159-8290.CD-NB2017-140. Epub 2017 Oct 04. PMID: 28978558.
Copy Download .nbib Format: NLM
FDA OKs Abemaciclib for ER+, HER2- Breast Cancer.

Cancer discovery

[No authors listed]
PMID: 28978559
Cancer Discov. 2017 Nov;7(11):OF1. doi: 10.1158/2159-8290.CD-NB2017-141. Epub 2017 Oct 04.

The FDA has approved abemaciclib for women with advanced or metastatic ER-positive, HER2-negative breast cancer whose disease has progressed on endocrine therapy. This is the third CDK4/6 inhibitor to get the agency's go-ahead in 2.5 years.

Cite
FDA OKs Abemaciclib for ER+, HER2- Breast Cancer. Cancer Discov. 2017;7(11):OF1doi: 10.1158/2159-8290.CD-NB2017-141.
(2017). FDA OKs Abemaciclib for ER+, HER2- Breast Cancer. Cancer discovery, 7(11), OF1. https://doi.org/10.1158/2159-8290.CD-NB2017-141
"FDA OKs Abemaciclib for ER+, HER2- Breast Cancer." Cancer discovery vol. 7,11 (2017): OF1. doi: https://doi.org/10.1158/2159-8290.CD-NB2017-141
FDA OKs Abemaciclib for ER+, HER2- Breast Cancer. Cancer Discov. 2017 Nov;7(11):OF1. doi: 10.1158/2159-8290.CD-NB2017-141. Epub 2017 Oct 04. PMID: 28978559.
Copy Download .nbib Format: NLM
Profiling Response, Resistance to Immunotherapy.

Cancer discovery

[No authors listed]
PMID: 28356263
Cancer Discov. 2017 May;7(5):OF2. doi: 10.1158/2159-8290.CD-NB2017-045. Epub 2017 Mar 29.

In a longitudinal analysis of patients with metastatic melanoma who received sequential therapies targeting CTLA-4, then PD-1 upon disease progression, researchers have discovered that high copy-number loss in recurrent regions of the tumor genome is associated with resistance to...

Cite
Profiling Response, Resistance to Immunotherapy. Cancer Discov. 2017;7(5):OF2doi: 10.1158/2159-8290.CD-NB2017-045.
(2017). Profiling Response, Resistance to Immunotherapy. Cancer discovery, 7(5), OF2. https://doi.org/10.1158/2159-8290.CD-NB2017-045
"Profiling Response, Resistance to Immunotherapy." Cancer discovery vol. 7,5 (2017): OF2. doi: https://doi.org/10.1158/2159-8290.CD-NB2017-045
Profiling Response, Resistance to Immunotherapy. Cancer Discov. 2017 May;7(5):OF2. doi: 10.1158/2159-8290.CD-NB2017-045. Epub 2017 Mar 29. PMID: 28356263.
Copy Download .nbib Format: NLM
FDA Approves Second CAR T-cell Therapy.

Cancer discovery

[No authors listed]
PMID: 29113977
Cancer Discov. 2018 Jan;8(1):5-6. doi: 10.1158/2159-8290.CD-NB2017-155. Epub 2017 Nov 07.

The FDA approved the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel, making it the second such treatment for blood cancers in the United States. The therapy is indicated for adults with certain non-Hodgkin lymphomas who have tried at least...

Cite
FDA Approves Second CAR T-cell Therapy. Cancer Discov. 2017;8(1):5-6doi: 10.1158/2159-8290.CD-NB2017-155.
(2018). FDA Approves Second CAR T-cell Therapy. Cancer discovery, 8(1), 5-6. https://doi.org/10.1158/2159-8290.CD-NB2017-155
"FDA Approves Second CAR T-cell Therapy." Cancer discovery vol. 8,1 (2018): 5-6. doi: https://doi.org/10.1158/2159-8290.CD-NB2017-155
FDA Approves Second CAR T-cell Therapy. Cancer Discov. 2018 Jan;8(1):5-6. doi: 10.1158/2159-8290.CD-NB2017-155. Epub 2017 Nov 07. PMID: 29113977.
Copy Download .nbib Format: NLM
Start-ups Bring AI to Pathology.

Cancer discovery

[No authors listed]
PMID: 29475882
Cancer Discov. 2018 Apr;8(4):376. doi: 10.1158/2159-8290.CD-NB2018-019. Epub 2018 Feb 23.

New startups are developing pattern-recognition algorithms that could one day help pathologists more accurately spot tumors on digitized tissue images, thereby aiding in diagnosis, treatment, drug discovery, and more.

Cite
Start-ups Bring AI to Pathology. Cancer Discov. 2018;8(4):376doi: 10.1158/2159-8290.CD-NB2018-019.
(2018). Start-ups Bring AI to Pathology. Cancer discovery, 8(4), 376. https://doi.org/10.1158/2159-8290.CD-NB2018-019
"Start-ups Bring AI to Pathology." Cancer discovery vol. 8,4 (2018): 376. doi: https://doi.org/10.1158/2159-8290.CD-NB2018-019
Start-ups Bring AI to Pathology. Cancer Discov. 2018 Apr;8(4):376. doi: 10.1158/2159-8290.CD-NB2018-019. Epub 2018 Feb 23. PMID: 29475882.
Copy Download .nbib Format: NLM
MEK Binding to KSR Promotes Allosteric Activation of BRAF.

Cancer discovery

[No authors listed]
PMID: 29475885
Cancer Discov. 2018 Apr;8(4):385. doi: 10.1158/2159-8290.CD-RW2018-033. Epub 2018 Feb 23.

KSR-MEK complexes allosterically activate BRAF, which then phosphorylates a second MEK molecule.

Cite
MEK Binding to KSR Promotes Allosteric Activation of BRAF. Cancer Discov. 2018;8(4):385doi: 10.1158/2159-8290.CD-RW2018-033.
(2018). MEK Binding to KSR Promotes Allosteric Activation of BRAF. Cancer discovery, 8(4), 385. https://doi.org/10.1158/2159-8290.CD-RW2018-033
"MEK Binding to KSR Promotes Allosteric Activation of BRAF." Cancer discovery vol. 8,4 (2018): 385. doi: https://doi.org/10.1158/2159-8290.CD-RW2018-033
MEK Binding to KSR Promotes Allosteric Activation of BRAF. Cancer Discov. 2018 Apr;8(4):385. doi: 10.1158/2159-8290.CD-RW2018-033. Epub 2018 Feb 23. PMID: 29475885.
Copy Download .nbib Format: NLM
Crowdsourcing to Curb Bad Science.

Cancer discovery

[No authors listed]
PMID: 26272490
Cancer Discov. 2015 Oct;5(10):1008. doi: 10.1158/2159-8290.CD-NB2015-118. Epub 2015 Aug 13.

No abstract available.

Cite
Crowdsourcing to Curb Bad Science. Cancer Discov. 2015;5(10):1008doi: 10.1158/2159-8290.CD-NB2015-118.
(2015). Crowdsourcing to Curb Bad Science. Cancer discovery, 5(10), 1008. https://doi.org/10.1158/2159-8290.CD-NB2015-118
"Crowdsourcing to Curb Bad Science." Cancer discovery vol. 5,10 (2015): 1008. doi: https://doi.org/10.1158/2159-8290.CD-NB2015-118
Crowdsourcing to Curb Bad Science. Cancer Discov. 2015 Oct;5(10):1008. doi: 10.1158/2159-8290.CD-NB2015-118. Epub 2015 Aug 13. PMID: 26272490.
Copy Download .nbib Format: NLM
$100M Africa Initiative Targets Childhood Cancer.

Cancer discovery

[No authors listed]
PMID: 28331005
Cancer Discov. 2017 May;7(5):447-448. doi: 10.1158/2159-8290.CD-NB2017-038. Epub 2017 Mar 22.

The Bristol-Myers Squibb Foundation have teamed up with Texas Children's Cancer and Hematology Centers and Baylor College of Medicine on a $100 million initiative to improve pediatric cancer care in sub-Saharan Africa. Organizers are partnering with local governments to...

Cite
$100M Africa Initiative Targets Childhood Cancer. Cancer Discov. 2017;7(5):447-448doi: 10.1158/2159-8290.CD-NB2017-038.
(2017). $100M Africa Initiative Targets Childhood Cancer. Cancer discovery, 7(5), 447-448. https://doi.org/10.1158/2159-8290.CD-NB2017-038
"$100M Africa Initiative Targets Childhood Cancer." Cancer discovery vol. 7,5 (2017): 447-448. doi: https://doi.org/10.1158/2159-8290.CD-NB2017-038
$100M Africa Initiative Targets Childhood Cancer. Cancer Discov. 2017 May;7(5):447-448. doi: 10.1158/2159-8290.CD-NB2017-038. Epub 2017 Mar 22. PMID: 28331005.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1747 entries